OlorinabA drug candidate for the treatment of pain. Olorinab (APD371) is an investigational, oral, peripherally acting, highly selective, full agonist of the cannabinoid type 2 receptor (CB2). Olorinab is an internally discovered drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain associated with gastrointestinal disorders. This compound, through its selectivity for CB2 versus CB1, is under investigation for pain relief without psychoactive adverse effects.
TAKE A STAND AGAINST
Clinical TrialsOlorinab is an investigational drug and is not currently approved for use by any health authority.